<bill session="113" type="sr" number="97" updated="2016-10-25T16:18:18Z">
  <state datetime="2013-04-15">REFERRED</state>
  <status>
    <introduced datetime="2013-04-15"/>
  </status>
  <introduced datetime="2013-04-15"/>
  <titles>
    <title type="official" as="introduced">A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.</title>
    <title type="display">A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.</title>
  </titles>
  <sponsor bioguide_id="C000560"/>
  <cosponsors>
    <cosponsor bioguide_id="A000360" joined="2013-04-16"/>
    <cosponsor bioguide_id="M000355" joined="2013-04-15"/>
    <cosponsor bioguide_id="S000148" joined="2013-04-15"/>
  </cosponsors>
  <actions>
    <action datetime="2013-04-15">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2013-04-15" state="REFERRED">
      <text>Referred to the Committee on Health, Education, Labor, and Pensions.</text>
      <reference ref="CR S2654" label="text of measure as introduced"/>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSHR" name="Senate Health, Education, Labor, and Pensions" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="hr" session="113" relation="unknown" number="161"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2013-04-15T04:00:00Z" status="Introduced in Senate">Expresses the sense of the Senate that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations recognized by FDA as effective, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.</summary>
  <committee-reports/>
</bill>
